公开(公告)号：US20160058774A1

公开(公告)日：2016-03-03

申请号：US14464536

申请日：2014-08-20

申请人： Mohamed EL-ALFY ,  Fernand LABRIE ,  Louise BERGER

发明人： Mohamed EL-ALFY ,  Fernand LABRIE ,  Louise BERGER

IPC分类号： A61K31/5685 ,  A61K31/453

CPC分类号： A61K31/5685 ,  A61K31/453 ,  A61K31/519 ,  A61K31/566

摘要： Novel methods for treating or reducing the likelihood of acquiring vaginal dysfunctions, more particularly vaginal dryness and dyspareunia, leading to sexual dysfunction and low sexual desire and performance, in susceptible warm-blooded animals including humans involving administration of a sex steroid precursor. Further administration of estrogen or selective estrogen receptor modulator, particularly those selected from the group consisting of Raloxifene, Arzoxifene, Tamoxifen, Droloxifene, Toremifene, Iodoxifene, GW 5638, TSE-424, ERA-923, and lasofoxifene, and more particularly compounds having the general structure: is specifically disclosed for the medical treatment and/or inhibition of development of some of these above-mentioned diseases. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.

摘要翻译： 在涉及施用性类固醇前体的易感染的温血动物（包括人）中治疗或减少获得阴道功能障碍的可能性的更多方法，特别是阴道干燥和性交痛，导致性功能障碍和性欲降低和表现。 进一步施用雌激素或选择性雌激素受体调节剂，特别是选自雷洛昔芬，阿唑西芬，他莫昔芬，德洛昔芬，托瑞昔芬，碘多昔芬，GW 5638，TSE-424，ERA-923和拉索昔芬的那些，更具体地， 一般结构：具体公开用于治疗和/或抑制某些上述疾病的发展。 还公开了用于递送本发明有用的活性成分和试剂盒的药物组合物。